• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Takeda Pharmaceutical Ltd ADR (NY: TAK )

    13.11 +0.08 (+0.61%)
    Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 438,664
    Open 13.06
    Bid (Size) 12.94 (2)
    Ask (Size) 13.25 (1)
    Prev. Close 13.03
    Today's Range 13.06 - 13.16
    52wk Range 12.57 - 16.39
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report
    Blackstone Inc. is reportedly finalizing a deal to sell Alinamin Pharmaceutical to MBK Partners for $2.17 billion. Blackstone acquired Alinamin from Takeda in 2020. 
    Via Benzinga
    Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600
    Protagonist Therapeutics will join the SmallCap 600 on Wednesday. 
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities

    Performance

    YTD
    -8.58%
    -8.58%
    1 Month
    -1.87%
    -1.87%
    3 Month
    -3.10%
    -3.10%
    6 Month
    -8.58%
    -8.58%
    1 Year
    -16.02%
    -16.02%

    More News

    Read More
    Takeda Announces New Assignments of Directors
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
    Via Benzinga
    Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies
    Via Benzinga
    Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
    Via Talk Markets
    Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    7 F-Rated Stocks to Avoid at All Costs in June
    Via InvestorPlace
    Blackstone Weighs Sale Of Japanese Pharma Firm Alinamin: Report
    Via Benzinga
    Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
    Via Talk Markets
    Week in Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
    Via Talk Markets
    Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
    Via Benzinga
    Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.